Kishore Ahuja, MD
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Sanofi at 24.0% of the total.
Across 108 payments — averaging $31.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$815
- AstraZeneca$537
- GSK$408
- Boston Scientific$295
- Amarin Pharma, Inc.$228
- Regeneron Healthcare Solutions, Inc.$194
- plus $915 from 11 others
What the payments were for
- Food & beverage$3,35299%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 27 | $815 |
| AstraZeneca | 28 | $537 |
| GSK | 17 | $408 |
| Boston Scientific | 3 | $295 |
| Amarin Pharma, Inc. | 2 | $228 |
| Regeneron Healthcare Solutions, Inc. | 6 | $194 |
| Novo Nordisk | 7 | $162 |
| Bayer | 2 | $139 |
| Idorsia Pharmaceuticals US Inc | 1 | $125 |
| Avanir Pharmaceuticals, Inc. | 1 | $115 |
| Gilead | 1 | $108 |
| Biohaven Pharmaceuticals, Inc. | 1 | $75 |
| Biocryst US Sales Co., LLC | 5 | $74 |
| Aimmune Therapeutics, Inc. | 2 | $41 |
| Pfizer | 2 | $30 |
| Optinose US, Inc. | 2 | $25 |
| Incyte Corporation | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$606
- Vascepa$228
- WATCHMAN FLX$150
- TRELEGY ELLIPTA$125
- QUVIVIQ$125
- NUEDEXTA$115
- Epclusa$108
How this compares
$3,391 in reported general payments places this provider in the 60th percentile of 92 allergy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levocetirizine Dihydrochloride | 29 | $300 |
| Montelukast Sodium | 21 | $297 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 11 | $113 |
| Methylprednisolone | 14 | $84 |
Paid to pharmacies, not to this prescriber.
Other allergy in Bronx
- Yudhistira PersaudBronx$127K
- Marc BraunsteinHewlett$884K
- Allison RamseyRochester$643K
- Christopher SmithHorseheads$622K
- Anne MaitlandTarrytown$292K
- Michael KatlanAlbany$91K
- Michel AklJamestown$90K
- Juan SotomayorNorth Syracuse$64K
- Alan KaufmanMount Vernon$60K
- Alissa McInerneyAstoria$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.